Barriers to Prescribing Opioids in the Management of Chronic Breathlessness in COPD: A Review.

IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM
Emma Keogh, E Mark Williams
{"title":"Barriers to Prescribing Opioids in the Management of Chronic Breathlessness in COPD: A Review.","authors":"Emma Keogh,&nbsp;E Mark Williams","doi":"10.1080/15412555.2021.2000956","DOIUrl":null,"url":null,"abstract":"<p><p>In people with COPD breathlessness is a common symptom and if mistreated can result in poor physical health and reduced quality of life. While it is important to manage the breathlessness using non-pharmacological management, persistent breathlessness may be treated with opioids. However, some physicians are reluctant to prescribe opioids to manage breathlessness in COPD. The aim of this review is to report the views, attitudes and barriers (if any) of healthcare professionals towards using opioids to manage chronic breathlessness in COPD. A review of the relevant literature was undertaken, using CINAHL, ScienceDirect and PubMed databases. The selected literature was assessed for quality of study design and methods used. Eleven studies (three qualitative, three mixed-methods and five quantitative) were reviewed and three themes were identified. Opioid use for refractory breathlessness in COPD is likely under prescribed by health care professionals working in areas other than palliative care. Additionally, there is a lack of confidence in using opioids except in those with palliative care experience, who are more likely to believe opioids may be helpful. Barriers identified are a lack of training, education, inadequate guidelines and concerns surrounding respiratory depression and other side effects. Research on this topic is mainly comprised of interviews or surveys and is low to moderate quality. Further clinical trials are needed on this topic including the opinions of all prescribing health care professionals involved in the care of these patients. Additionally, guidelines should offer further advice on when to start opioids and which patients would benefit most from opioids.</p>","PeriodicalId":10704,"journal":{"name":"COPD: Journal of Chronic Obstructive Pulmonary Disease","volume":"18 6","pages":"713-722"},"PeriodicalIF":2.2000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"COPD: Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15412555.2021.2000956","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

In people with COPD breathlessness is a common symptom and if mistreated can result in poor physical health and reduced quality of life. While it is important to manage the breathlessness using non-pharmacological management, persistent breathlessness may be treated with opioids. However, some physicians are reluctant to prescribe opioids to manage breathlessness in COPD. The aim of this review is to report the views, attitudes and barriers (if any) of healthcare professionals towards using opioids to manage chronic breathlessness in COPD. A review of the relevant literature was undertaken, using CINAHL, ScienceDirect and PubMed databases. The selected literature was assessed for quality of study design and methods used. Eleven studies (three qualitative, three mixed-methods and five quantitative) were reviewed and three themes were identified. Opioid use for refractory breathlessness in COPD is likely under prescribed by health care professionals working in areas other than palliative care. Additionally, there is a lack of confidence in using opioids except in those with palliative care experience, who are more likely to believe opioids may be helpful. Barriers identified are a lack of training, education, inadequate guidelines and concerns surrounding respiratory depression and other side effects. Research on this topic is mainly comprised of interviews or surveys and is low to moderate quality. Further clinical trials are needed on this topic including the opinions of all prescribing health care professionals involved in the care of these patients. Additionally, guidelines should offer further advice on when to start opioids and which patients would benefit most from opioids.

阿片类药物在COPD慢性呼吸困难治疗中的障碍:综述。
慢性阻塞性肺病患者呼吸困难是一种常见症状,如果治疗不当,可能导致身体健康状况不佳和生活质量下降。虽然使用非药物管理控制呼吸困难很重要,但持续呼吸困难可使用阿片类药物治疗。然而,一些医生不愿意开阿片类药物来治疗COPD患者的呼吸困难。本综述的目的是报告医疗保健专业人员对使用阿片类药物治疗COPD慢性呼吸困难的看法、态度和障碍(如果有的话)。使用CINAHL、ScienceDirect和PubMed数据库对相关文献进行了回顾。对所选文献的研究设计质量和使用的方法进行评估。十一项研究(三个定性,三个混合方法和五个定量)进行了审查,并确定了三个主题。阿片类药物用于慢性阻塞性肺病难治性呼吸困难可能是由在姑息治疗以外领域工作的卫生保健专业人员规定的。此外,除了那些有姑息治疗经验的人之外,人们对使用阿片类药物缺乏信心,他们更有可能相信阿片类药物可能有帮助。确定的障碍是缺乏培训、教育、指南不足以及对呼吸抑制和其他副作用的担忧。关于这一主题的研究主要是由访谈或调查组成,质量低到中等。这一主题需要进一步的临床试验,包括所有参与这些患者护理的处方卫生保健专业人员的意见。此外,指南应就何时开始使用阿片类药物以及哪些患者将从阿片类药物中获益最多提供进一步的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
38
审稿时长
6-12 weeks
期刊介绍: From pathophysiology and cell biology to pharmacology and psychosocial impact, COPD: Journal Of Chronic Obstructive Pulmonary Disease publishes a wide range of original research, reviews, case studies, and conference proceedings to promote advances in the pathophysiology, diagnosis, management, and control of lung and airway disease and inflammation - providing a unique forum for the discussion, design, and evaluation of more efficient and effective strategies in patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信